Comments
Dr Reddy’s Laboratories announced reduction in prices of its cardiovascular drug, Cidmus, a a combination drug of sacubitril and valsartan, indicated for heart failure patients with reduced ejection fraction.
The Hyderabad-based Dr. Reddy’s Cidmus tablets are available in three strengths – 50mg, 100mg and 200mg, to be taken twice a day. Following the price reduction, Cidmus will be priced at ₹29 for 50mg (down from ₹78.32), ₹49 for 100mg (down from ₹83.86) and ₹79 for 200mg (down from ₹96.71) per tablet.
The product will be manufactured in-house. The Active Pharmaceutical Ingredient (API) of Cidmus is manufactured at a USFDA- approved facility.
There is a growing incidence of chronic diseases in India with estimated 8-10 million heart failure patients.
For domestic market, Dr. Reddy’s acquired the cardiovascular brand Cidmus from Novartis AG in 2022 and reached over 1 lakh patients with 32 per cent market share, according to a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.